SPIOLTO® Respimat® (tiotropium & olodaterol)
COPD
What is COPD?
Chronic obstructive pulmonary disease (COPD) is a group of long-term conditions caused by damage to the lungs, which can make it difficult to breathe.1,2
In patients with COPD, the air sacs inside their lungs may collapse when breathing in and the airways may become inflamed and narrowed.1,2
Symptoms
Patients with COPD may experience some of the following symptoms, which can make it harder to carry out everyday tasks:2
How is COPD treated?
Inhaled medicines are usually used to treat COPD to help patients manage their symptoms.2,3
What is SPIOLTO Respimat (tiotropium & olodaterol)?
SPIOLTO Respimat (tiotropium & olodaterol) is a medication used in the treatment of COPD to help patients breathe more easily. It contains the active ingredients tiotropium & olodaterol. These belong to a group of medicines called long-acting bronchodilators. Tiotropium belongs to the subgroup of anticholinergics; olodaterol belongs to the subgroup of long-acting beta2 agonists. SPIOLTO Respimat helps to open the airways and make it easier to get air in and out of the lungs.3
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Some uncommon side effects (may affect up to 1 in 100 people) which may be experienced when taking SPIOLTO Respimat (tiotropium & olodaterol) include faster heart beat (tachycardia), dizziness, headache, cough, hoarseness (dysphonia), and dry mouth.3
If any of the following occurs, please stop taking this medicine and consult your doctor immediately:
Immediate allergic reactions to SPIOLTO Respimat are rare (they may affect up to 1 in 1,000 people). These reactions may occur individually or as part of a severe allergic reaction (anaphylactic reaction) after administration of SPIOLTO Respimat. These include rash, nettle rash (urticaria), swelling of the mouth and face, sudden difficulties in breathing (angioneurotic oedema) or other hypersensitivity reactions (such as sudden reduction of your blood pressure or light headedness).
As with all inhaled medications, tightness of the chest, associated with coughing, wheezing or breathlessness may occur immediately after inhalation (paradoxical bronchospasm). The frequency cannot be estimated from the available data.
Seeing halos around lights or coloured images in association with red eyes (glaucoma). The frequency cannot be estimated from the available data.
Blockage of intestines or absence of bowel movements (intestinal obstruction, including ileus paralytic). The frequency cannot be estimated from the available data.3
Please refer to the patient information leaflet for further information about possible side effects.
References
-
1.
Asthma + Lung UK. What is COPD? Available from: https://www.asthmaandlung.org.uk/conditions/copd-chronic-obstructive-pulmonary-disease/what-copd (Accessed November 2024).
-
2.
NHS Choices. Chronic obstructive pulmonary disease (COPD). Available from: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/ (Accessed November 2024).
-
3.
SPIOLTO Respimat (tiotopium & olodaterol) Patient Information Leaflet.
Where can I find more information about SPIOLTO Respimat (tiotropium & olodaterol)?
Patient Information Leaflet
The Patient Information Leaflet is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using this medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Patient Information Leaflet
Summary of Product Characteristics
The Summary of Product Characteristics (SmPC) tells healthcare professionals, such as doctors, pharmacists and nurses, how to prescribe and use this medicine correctly. The information in the Patient Information Leaflet and Summary of Product Characteristics are not intended to replace the opinion of a healthcare professional.
NP-GB-103748 | November 2024
